Small-molecule drug developer Sareum said it would next month present new trial data from a cancer treatment research programme at a key industry conference in Boston. The pre-clinical data was associated with the company's SDC-1802 TYK2/JAK1 inhibitor cancer research programme. It would be presented at the American Association for Cancer Research, National Cancer Institute, European Organisation for Research and Treatment of Cancer International Conference, to be held 26-30 October. Chief executive Tim Mitchell would on 29 October present a poster that described how SAR-20351, a novel selective TYK2/JAK1 inhibitor discovered by Sareum, significantly reduced tumour growth in disease models of many cancers, including those of the pancreas, colon, skin and kidney, plus B-cell lymphoma. SAR-20351 was formally selected as a pre-clinical development candidate SDC-1802 in September 2018.
Sign up to our
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
UK 350 Risers and Fallers
Tweets not available.